NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Femasys Inc. (FEMY) Stock Analysis

Femasys Inc. (FEMY) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FEMY

$1.65

−$0.02 (−1.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FEMY with… →

FEMY Key Statistics

As of Oct 21, 2026
Trading
Open
$1.71
Previous Close
$1.67
Day's Range
1.64–1.72
52-Week Range
1.46–22.20
Volume
32.51K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−2.16
Valuation
Market Cap
$13.82M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.28
Financials (FY)
Revenue (FY)
$2.29M+40.77%
Net Income (FY)
−$18.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.38M
1-Year Return
−87.09%
Dividend and dates
Avg Volume
727.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FEMY closed at $1.65, −87.09% over 1 year.

Femasys Inc. (FEMY) has a market capitalization of $13.82M.

In fiscal 2025, FEMY reported revenue of $2.29M.

FEMY Stock Return by Calendar Year

Femasys Inc. (FEMY) return since Jun 2021: what $10,000 became

1 year
$10,000 $1,291
−87.09%
5 years
$10,000 $116
−98.84%
Since Jun 2021
$10,000 $69
−99.31%

If you had invested $10,000 in Femasys Inc. (FEMY) at the close on June 18, 2021, the earliest close on record here, it would have been worth $69 at the close on October 21, 2026: −99.31% in total, −60.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−85.68%
2025−47.64%
2024+12.82%
2023+8.33%
2022−76.92%
2021 (partial year)−67.50%

As of October 21, 2026.

FEMY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.29M−$18.63M−812.3%
2024$1.63M−$18.82M−1,155.0%
2023$1.07M−$14.25M−1,329.1%
2022$1.21M−$11.39M−944.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.29M$1.42M−$17.59M−$18.63M−812.3%
2024$1.63M$1.08M−$17.79M−$18.82M−1,155.0%
2023$1.07M$691.90K−$14.51M−$14.25M−1,329.1%
2022$1.21M$764.28K−$11.60M−$11.39M−944.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FEMY Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricFEMYMedical Instruments & Supplies medianvs median
P/S ratio6.012.60131% above

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Femasys Inc. (FEMY) is capitalised at $13.82M on the latest close. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 51.

The most recent close on file for FEMY is $1.65, dated October 21, 2026. That is −$0.02 (−1.20%) against the previous close. Over the past 52 weeks the price has ranged from $1.46 to $22.20. The latest close sits 13.01% above that 52-week low.

Financial Health

In fiscal 2025, Femasys Inc. reported revenue of $2.29M. That is +40.77% against the prior fiscal year, when revenue was $1.63M. The same year closed with a net loss of $18.63M. Trailing earnings per share are −3.28.

Across the 4 fiscal years on file, revenue moves from $1.21M in 2022 to $2.29M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 6.01 times revenue. On price-to-sales that is 131.34% above the Medical Instruments & Supplies median of 2.6. The medians here are taken across 50 Medical Instruments & Supplies companies that report the metric.

The trailing one-year total return is −87.09%. Measured over 5 years, that is −59.00% a year compounded. Beta against the wider market is reported at −2.16. Daily returns over the trailing 5 years annualize to a volatility of 204.91%.

Growth & Income

No dividend is on file for FEMY.

2026 is still running; the total return is −85.68% year to date. The strongest complete calendar year on file is 2024 at +12.82%; the weakest is 2022 at −76.92%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Femasys Inc. (FEMY) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Femasys Inc. FEMY $13.82M —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Femasys Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Femasys Inc.

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Visit website →